P20248 (CCNA2_HUMAN) Homo sapiens (Human)
Cyclin-A2 UniProtKBInterProSTRINGInteractive Modelling
432 aa; Sequence (Fasta)
It is possible new templates exist for this target since these models were created.
Available Structures
106 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. |
Heteromer P24941; | 1×75X; 2×MG; | ||||
| Assess | ||||||
| Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. |
Heteromer P24941; | 1×2WC; 1×MG; | ||||
| Assess | ||||||
| Crystal Structure Analysis of human CDK2 and CCNA2 complex |
Heteromer P24941; | 1×ZGY; | ||||
| Assess | ||||||
| The crystal structure of CDK2 cyclin A in complex with a substrate peptide derived from CDC modifie… |
Heteromer P24941; Q99741; | 1×ATP; 1×SO4; 2×GOL; | ||||
| Assess | ||||||
| Cdk2/cyclin A/p27-KID-deltaC |
Heteromer P24941; P46527; | 1×SO4; | ||||
| Assess | ||||||
| CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX |
Heteromer P24941; | 1×ATP; | ||||
| Assess | ||||||
| THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR |
Heteromer P24941; | 1×107; | ||||
| Assess | ||||||
| Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. |
Heteromer P24941; | 1×G6T; | ||||
| Assess | ||||||
| Crystal structure of Cyclin-dependent kinase 2/cyclin A in complex with 3,5,7-Substituted pyrazolo[… |
Heteromer P24941; | 1×D5P; 1×GOL; 4×EDO; 2×PEG; 1×SGM; | ||||
| Assess | ||||||
| CDK2/cyclin A2 in complex with an imidazo[1,2-c]pyrimidin-5-one inhibitor |
Heteromer P24941; | 1×R7B; 6×EDO; 1×NA; | ||||
| Assess | ||||||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6086 |
Heteromer P24941; | 1×6CP; | ||||
| Assess | ||||||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6102 |
Heteromer P24941; | 1×4SP; | ||||
| Assess | ||||||
| Thr 160 phosphorylated CDK2 K89D, Q131E - human cyclin A3 complex with the inhibitor RO3306 |
Heteromer P24941; | 1×1RO; 1×DMS; 1×SGM; | ||||
| Assess | ||||||
| CDK2/Cyclin A covalent complex with 6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-am… |
Heteromer P24941; | 1×55S; | ||||
| Assess | ||||||
| REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors |
Heteromer P24941; | 1×MTZ; 1×GVC; | ||||
| Assess | ||||||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-pu… |
Heteromer P24941; | 1×N20; 1×SGM; 1×MG; | ||||
| Assess | ||||||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU2058 |
Heteromer P24941; | 1×CMG; | ||||
| Assess | ||||||
| Thr 160 phosphorylated CDK2 Q131E - human cyclin A3 complex with ATP |
Heteromer P24941; | 2×MG; 1×ATP; 1×SGM; | ||||
| Assess | ||||||
| Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design |
Heteromer P24941; | 1×CK2; | ||||
| Assess | ||||||
| Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design |
Heteromer P24941; | 1×CK8; | ||||
| Assess | ||||||
| CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR4455 |
Heteromer P24941; | 1×FCQ; 3×EDO; 1×CL; 1×BR; 1×PG4; 1×SGM; 1×PGE; | ||||
| Assess | ||||||
| PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX |
Heteromer P24941; | 2×ATP; 2×MG; | ||||
| Assess | ||||||
| CDK2/CyclinA in complex with an 11-residue recruitment peptide from p27 |
Heteromer P24941; P46527; | |||||
| Assess | ||||||
| The structure of phospho-CDK2/cyclin A in complex with the inhibitor 4,5,6,7-tetrabromobenzotriazol… |
Heteromer P24941; | 1×TBS; | ||||
| Assess | ||||||
| CDK2/CyclinA in complex with an 11-residue recruitment peptide from p53 |
Heteromer P04637; P24941; | |||||
| Assess | ||||||
| P27(KIP1)/CYCLIN A/CDK2 COMPLEX |
Heteromer P24941; P46527; | 1×SO4; | ||||
| Assess | ||||||
| Structure of CDK2/Cyclin A with PNU-292137 |
Heteromer P24941; | 1×SO4; 1×292; | ||||
| Assess | ||||||
| THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A |
Heteromer P24941; | 1×UCN; | ||||
| Assess | ||||||
| Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design |
Heteromer P24941; | 1×CK7; | ||||
| Assess | ||||||
| Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Ile-Phe-NH2 |
Heteromer P24941; | |||||
| Assess | ||||||
| Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor |
Heteromer P24941; | 1×C95; | ||||
| Assess | ||||||
| Structure of phopsho-CDK2-cyclin A in complex with an ATP-competitive inhibitor |
Heteromer P24941; | 1×6ZK; 1×SGM; 1×MG; | ||||
| Assess | ||||||
| STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 |
Heteromer P24941; | 1×529; 1×SO4; | ||||
| Assess | ||||||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-pu… |
Heteromer P24941; | 1×N41; 1×SGM; 1×MG; | ||||
| Assess | ||||||
| Thr 160 phosphorylated CDK2 - Human cyclin A3 complex with the inhibitor indirubin-5-sulphonate bou… |
Heteromer P24941; | 1×INR; | ||||
| Assess | ||||||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with the inhibitor NU6094 |
Heteromer P24941; | 1×2A6; | ||||
| Assess | ||||||
| CDK2/CyclinA in complex with a 9 residue recruitment peptide from E2F |
Heteromer P24941; Q01094; | |||||
| Assess | ||||||
| CDK2/Cyclin A in complex with an 11-residue recruitment peptide from retinoblastoma-associated prot… |
Heteromer P06400; P24941; | |||||
| Assess | ||||||
| Cyclin A binding groove inhibitor Ac-Arg-Arg-Leu-Asn-(m-Cl-Phe)-NH2 |
Heteromer P24941; | |||||
| Assess | ||||||
| Optimisation of 6,6-Dimethyl Pyrrolo 3,4-c pyrazoles: Identification of PHA-793887, a Potent CDK In… |
Heteromer P24941; | 1×SO4; 1×889; | ||||
| Assess | ||||||
| Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with the inhibitor NU6102 |
Heteromer P24941; | 1×4SP; 1×SGM; | ||||
| Assess | ||||||
| PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A |
Heteromer P24941; | 2×MN; 2×ATP; | ||||
| Assess | ||||||
| Cyclin A binding groove inhibitor Ace-Arg-Lys-Leu-Phe-Gly |
Heteromer P24941; | |||||
| Assess | ||||||
| REPLACE: A strategy for Iterative Design of Cyclin Binding Groove Inhibitors |
Heteromer P24941; | 1×C35; | ||||
| Assess | ||||||
| Cyclin A binding groove inhibitor H-Arg-Arg-Leu-Asn-(p-F-Phe)-NH2 |
Heteromer P24941; | |||||
| Assess | ||||||
| Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment sit… |
Heteromer P24941; | 1×MG; | ||||
| Assess | ||||||
| Crystal structure of the human CDK2 complexed with the triazolopyrimidine inhibitor |
Heteromer P24941; | 1×DT5; | ||||
| Assess | ||||||
| Crystal structure of phospho-CDK2 Cyclin A in complex with a peptide containing both the substrate … |
Heteromer P24941; Q99741; | 1×ATP; 1×MG; | ||||
| Assess | ||||||
| STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 |
Heteromer P24941; | 1×SO4; 1×514; | ||||
| Assess | ||||||
| Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor |
Heteromer P24941; | 1×C75; | ||||
| Assess | ||||||
| pCDK2/cyclin A in complex with MgADP, nitrate and peptide substrate |
Heteromer P24941; | 1×ATP; 1×MG; 1×NO3; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor |
Heteromer P24941; | 1×C85; | ||||
| Assess | ||||||
| Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design |
Heteromer P24941; | 1×X1N; | ||||
| Assess | ||||||
| CDK2/CyclinA in complex with an 11-residue recruitment peptide from p107 |
Heteromer P24941; P28749; | |||||
| Assess | ||||||
| STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO- 1H-PYRAZOLO[4,3-H] QUINAZ… |
Heteromer P24941; | 1×P49; | ||||
| Assess | ||||||
| Structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment sit… |
Heteromer P24941; | |||||
| Assess | ||||||
| Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. |
Heteromer P24941; | 1×4QE; | ||||
| Assess | ||||||
| Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design |
Heteromer P24941; | |||||
| Assess | ||||||
| Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design |
Heteromer P24941; | 1×MTW; | ||||
| Assess | ||||||
| Differential Binding Of Inhibitors To Active And Inactive Cdk2 Provides Insights For Drug Design |
Heteromer P24941; | 1×CK4; | ||||
| Assess | ||||||
| Cyclin A binding groove inhibitor H-Cit-Cit-Leu-Ile-(p-F-Phe)-NH2 |
Heteromer P24941; | |||||
| Assess | ||||||
| CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor |
Heteromer P24941; | 1×5BP; | ||||
| Assess | ||||||
| Cryo-EM structure of CDK2-CyclinA in complex with p27 from the SCFSKP2 E3 ligase Complex |
Heteromer P24941; P46527; | |||||
| Assess | ||||||
| Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: CUL1-RBX1-SKP1-SKP2… |
Heteromer P24941; P46527; P61024; P63208; Q13309; Q13616; | |||||
| Assess | ||||||
| Ubiquitin ligation to F-box protein substrates by SCF-RBR E3-E3 super-assembly: NEDD8-CUL1-RBX1-SKP… |
Heteromer P0CG48; P24941; P46527; P61024; P62877; P63208; P68036; Q13309; Q13616; Q15843; Q9Y4X5; | 9×ZN; 1×SY8; | ||||
| Assess | ||||||
| Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with ATP |
Heteromer P24941; | 1×ATP; 2×MG; 2×SGM; | ||||
| Assess | ||||||
| Thr 160 phosphorylated CDK2 Q131E - human cyclin A3 complex with the inhibitor RO3306 |
Heteromer P24941; | 1×1RO; 1×SGM; | ||||
| Assess | ||||||
| Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor |
Heteromer P24941; | 1×T3E; 1×SGM; | ||||
| Assess | ||||||
| Thr 160 phosphorylated CDK2 H84S, Q85M, Q131E - human cyclin A3 complex with ATP |
Heteromer P24941; | 1×ATP; 1×MG; | ||||
| Assess | ||||||
| Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with ATP |
Heteromer P24941; | 1×ATP; 2×MG; 1×SGM; | ||||
| Assess | ||||||
| Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. |
Heteromer P24941; | 1×JYM; 1×DTT; | ||||
| Assess | ||||||
| Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with the inhibitor NU6102 |
Heteromer P24941; | 1×4SP; | ||||
| Assess | ||||||
| Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor |
Heteromer P24941; | 1×T3C; 1×SO4; 2×SGM; | ||||
| Assess | ||||||
| Mechanism of CDK inhibition by active site phosphorylation: CDK2 Y15p T160p in complex with cyclin … |
Heteromer P24941; | 1×ATP; | ||||
| Assess | ||||||
| STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR |
Heteromer P24941; | 1×QQ2; 1×SGM; 1×MG; | ||||
| Assess | ||||||
| STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGU… |
Heteromer P24941; | 1×4SP; 1×SGM; | ||||
| Assess | ||||||
| Thr 160 phosphorylated CDK2 H84S, Q85M, Q131E - human cyclin A3 complex with the inhibitor RO3306 |
Heteromer P24941; | 1×1RO; 1×MG; | ||||
| Assess | ||||||
| Thr 160 phosphorylated CDK2 H84S, Q85M, K89D - human cyclin A3 complex with the inhibitor RO3306 |
Heteromer P24941; | 1×1RO; 1×SGM; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor |
Heteromer P24941; | 1×C94; | ||||
| Assess | ||||||
| Structure of CDK2/cyclin A M246Q, S247EN |
Heteromer P24941; | |||||
| Assess | ||||||
| Structure-based design of C8-substituted O6-cyclohexylmethoxyguanine CDK1 and 2 inhibitors. |
Heteromer P24941; | 1×SQ9; | ||||
| Assess | ||||||
| Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor |
Heteromer P24941; | 1×T7Z; 1×SGM; | ||||
| Assess | ||||||
| STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 |
Heteromer P24941; | 1×P48; | ||||
| Assess | ||||||
| Truncation and Optimisation of Peptide Inhibitors of CDK2, Cyclin A Through Structure Guided Design |
Heteromer P24941; | |||||
| Assess | ||||||
| Crystal structure of the Cyclin A-CDK2-ORC1 complex |
Heteromer P24941; Q13415; | 4×PO4; | ||||
| Assess | ||||||
| Thr 160 phosphorylated CDK2 WT - human cyclin A3 complex with the inhibitor RO3306 |
Heteromer P24941; | 1×1RO; | ||||
| Assess | ||||||
| Structure of CDK2-CYCLIN A with a Pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor |
Heteromer P24941; | 1×WXV; 1×SO4; | ||||
| Assess | ||||||
| STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 |
Heteromer P24941; | 1×SBC; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure apo CDK2/cyclin A |
Heteromer P24941; | |||||
| Assess | ||||||
| Crystal Structure of the CDK2/Cyclin A complex with oxindole inhibitor |
Heteromer P24941; | 1×60K; 2×DTT; | ||||
| Assess | ||||||
| Cdk2/Cyclin A complexed with a thiophene carboxamide inhibitor |
Heteromer P24941; | 1×BLZ; | ||||
| Assess | ||||||
| CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor |
Heteromer P24941; | 1×PO5; | ||||
| Assess | ||||||
| Cdk2/CyclinA complexed with a imidazo triazin-2-amine |
Heteromer P24941; | 1×T2A; | ||||
| Assess | ||||||
| Cryo-EM structure of SKP1-SKP2-CKS1-CDK2-CyclinA-p27KIP1 Complex |
Heteromer P24941; P46527; P61024; P63208; Q13309; | |||||
| Assess | ||||||
| Structure of human Thr160-phospho CDK2/cyclin A complexed with a 6-cyclohexylmethyloxy-2-anilino-pu… |
Heteromer P24941; | 1×N76; 1×SGM; 1×MG; | ||||
| Assess | ||||||
| CDK2/cyclin A2 in complex with open-ring 5-nitrosopyrimidine inhibitor LC436 |
Heteromer P24941; | 1×K4W; 2×NA; 2×GOL; | ||||
| Assess | ||||||
| CDK-2-Cyclin complex with indazole inhibitor 9 bound at its active site |
Heteromer P24941; | 4×GOL; 4×EZV; 2×SO4; | ||||
| Assess | ||||||
| CDK2/cyclin A2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor LGR6768 |
Heteromer P24941; | 1×P2V; 2×GOL; 1×EDO; | ||||
| Assess | ||||||
| STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR |
Heteromer P24941; | 1×4SP; 1×SGM; 1×MG; | ||||
| Assess | ||||||
| Structure of CDK2 in complex with cyclin A and a 2-amino-4-heteroaryl- pyrimidine inhibitor |
Heteromer P24941; | 1×T9N; 1×SO4; | ||||
| Assess | ||||||
| STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-N… |
Heteromer P24941; | 1×ST8; 1×SGM; | ||||
| Assess | ||||||
| CDK2/Cyclin A in complex with compound 73 |
Heteromer P24941; | 1×72L; | ||||
| Assess | ||||||
| CDK2/cyclin A2 in complex with 3H-pyrazolo[4,3-f]quinoline-based derivative HSD1368 |
Heteromer P24941; | 1×T1T; 1×NO3; 1×SO4; | ||||
| Assess | ||||||
| Cryo-EM structure of the APC/C-Cdc20-Cdk2-cyclinA2-Cks2 complex, the D1 box class |
Heteromer P30260; P60006; Q12834; Q13042; Q8NHZ8; Q96DE5; Q9BS18; Q9H1A4; Q9NYG5; Q9UJX2; Q9UJX3; Q9UJX4; Q9UJX5; Q9UJX6; Q9UM13; | |||||
| Assess | ||||||
| Cryo-EM structure of the APC/C-Cdc20-Cdk2-cyclinA2-Cks2 complex, the D2 box class |
Heteromer P30260; P60006; Q12834; Q13042; Q8NHZ8; Q96DE5; Q9BS18; Q9H1A4; Q9NYG5; Q9UJX2; Q9UJX3; Q9UJX4; Q9UJX5; Q9UJX6; Q9UM13; | |||||
| Assess | ||||||
| N-terminus of Skp2 bound to Cyclin A | homo-4-mer | |||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8bya.1.B | monomer | 0.79 | 100.00 | |||
| Assess | ||||||